Skip to main content

Table 2 Parameter estimates in pediatric and young adult patients

From: Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Parameter

Pediatric/young adult model

Adult model

Estimate

%RSE

Shrinkage (%)

Estimate

%RSE

Shrinkage (%)

CL (L/day)

0.217

5

 

0.200

2

 

V1 (L)

3.01

4

 

3.28

2

 

V2 (L)

1.36

11

 

3.63

4

 

Q (L/day)

0.183

18

 

0.546

8

 

Weight on CL

0.795

8

 

0.808

8

 

Albumin on CL

−1.18

20

 

−1.12

10

 

Tumor burden on CL

0.122

35

 

0.125

17

 

Positive ADA on CL

1.23

8

 

1.16

25

 

Weight on V1

0.766

8

 

0.559

8

 

Albumin on V1

−0.566

29

 

−0.350

21

 

Sex (female) on V1

NE

–

 

− 0.129

16

 

Sex (female) on V2

NE

–

 

−0.272

16

 

Proportional residual variance

0.051

32

12

0.043

7

9

Additive residual variance

68.9

109

12

16.6

39

9

BSV for CL

0.0458

33

21

0.0867

9

9

BSV for V1

0.0140

65

43

0.0328

18

17

BSV for V2

0.311

63

39

0.114

25

33

Correlation of BSVs for CL, V1

0.510

–

 

0.341

  

Correlation of BSVs for CL, V2

NE

–

 

−0.236

  

Correlation of BSVs for V1, V2

NE

–

 

0.434

  

Objective function

3637

  

40,748

  
  1. Abbreviations: %RSE Percent relative standard error, ADA Anti-drug antibody, BSV Between-subject variability, CL Clearance, NE Not evaluated, Q Inter-compartmental clearance, V1 Volume of the central compartment, V2 Volume of the peripheral compartment
Back to article page